Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMM5JAN)

Drug Name
LY2495655 Drug Info
Indication
Disease Entry ICD 11 Status REF
Disuse muscle atrophy 8B61 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMM5JAN

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Growth/differentiation factor 8 (GDF-8) TTSWPH8 GDF8_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Growth/differentiation factor 8 (GDF-8) DTT MSTN -0.737 -1.737 1.433 -1.322
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Disuse muscle atrophy
ICD Disease Classification 8B61
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Growth/differentiation factor 8 (GDF-8) DTT MSTN 1.64E-01 -0.06 -0.06
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01505530) A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer. U.S. National Institutes of Health.
2 Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.